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Figure 1. Higher symptom burden associated with increased median viral
load
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321 S317tacrolimus 0.02 mg/kg/day from day -3 for a target level of 5-
10 ng/ml. In absence of signiﬁcant GVHD, tacrolimus was
tapered between days 60 and 100 and sirolimus between
days 100 and 180. Characteristics of patients are displayed in
Table 1. All patients reached engraftment after a median of 15
days (range 12-22) for neutrophils > 0.5109/L and 18 days
(range 17-44) for platelets >20109/L. There were no deaths
before day +100. 1 patient developed grade III aGVHD and 8
patients developed cGVHD. All patients had complete
chimerism and were in complete remission at day +100
assessment. Median follow up is 18.4 months (8.9-63.6).
There have been 5 relapses and 3 patients received donor
lymphocyte infusion as part of the treatment strategy. 2
patients died from refractory disease, 1 patient died from
pulmonary embolism, 2 patients are alive not in remission
and 5 patients are alive with no evidence of disease. No pa-
tient has died of GVHD or infectious complications. Median
progression free and overall survival are 10.2 (95% C.I. 4.5-
63.6) and 18.4 (95% C.I. 8.9-63.6, Figure 1) months respec-
tively. We conclude that a regimen with RIT and mTOR
inhibition incorporated into allo-HCT could lead to adequate
disease control with low risk of aGVHD. Strategies targeting
host B-cells in combination with mTOR inhibitor should be
explored further in the development of allo-HCT for treat-
ment of advanced B-cell lymphomas.Figure 2. Lower viral load at initial test is associated with lack of symptoms at
time of initial test (A) and throughout viral shedding episode (B).459
Viral Load in Hematopoietic Cell Transplant Recipients
Infected with Human Rhinovirus Correlates with Burden
of Symptoms
Alpana Waghmare 1,2,3, Jane M. Kuypers 2, Hu Xie 3,
Wendy Leisenring 3, Angela P. Campbell 4, Keith R. Jerome 2,3,
Janet A. Englund 1,2, Michael J. Boeckh 2,3. 1 Seattle Children’s
Hospital, Seattle, WA; 2University of Washington, Seattle, WA;
3 Fred Hutchinson Cancer Research Center, Seattle, WA;
4 Centers for Disease Control, Atlanta, GA
Background: Human rhinovirus (HRV), the virus predomi-
nantly associated with the common cold, is the most
common virus detected from respiratory specimens in he-
matopoietic cell transplant (HCT) recipients, largely due to
the development of new sensitive molecular viral detection
techniques. In immunocompetent children, HRV viral load
from nasal specimens correlates with disease severity,
namely the development of pneumonia, hospital admission,
and oxygen requirement. Prospective studies describing the
relationship between viral load and symptoms in immuno-
compromised hosts, however, are limited.
Methods: We conducted a prospective surveillance study of
allogeneic HCT recipients, in which upper respiratory sam-
ples and symptom surveys were collected weekly for the ﬁrst
100 days following HCT, then every 3 months or with new
respiratory symptoms thereafter for 1 year. Symptom sur-
veys included assessment of 11 respiratory symptoms
including rhinorrhea, sinus congestion, post-nasal drip,
dyspnea, cough, wheezing, sputum production, pharyngitis,
sneezing, watery eyes and ear pain. Respiratory samples
were tested by real-time RT-PCR targeting the highly
conserved 50 noncoding region. RT-PCR cycle threshold (CT)
values were used as a proxy measure of viral load. Only pa-
tients with symptom survey results within 3 days of initial
sample collection were considered eligible for analysis.
Results: Of 471 patients included in the study, 153 (32%)
were positive for HRV at least once during the study dura-
tion; 128 patients had a reported viral load at the initial
positive sample and had a symptom survey completedwithin 3 days of the initial positive sample. Comparison of
median CT values of initial positive samples of patients with
no symptoms, 1-2 symptoms, and 3 or greater symptoms
revealed the presence of fewer symptoms was associated
with higher CT values (i.e. lower viral loads, p¼ 0.036, Figure
1). Patients whose initial CT value was high (35) were more
likely to be asymptomatic at initial positive test result than
patients with lower initial CT values (25-30 and <25) (48%
vs. 26% vs. 17%, p ¼ 0.064, Figure 2A) and were more likely to
remain asymptomatic throughout the viral shedding episode
(27% vs. 7% vs. 9%, p ¼ 0.033, Figure 2B).
Conclusions: No or few symptoms at the time of initial
viral positivity were associated with lower viral loads
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number of symptoms (3) was associated with a higher
viral load. Lower viral load at initial surveillance testing
correlated with an increased likelihood of being asymp-
tomatic initially and remaining asymptomatic throughout
the viral shedding episode. These results provide initial
support for the use of viral load as a clinical endpoint in
interventional trials.460
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Background: Tacrolimus is extensively employed in allo-
geneic hematopoietic cell transplant (alloHCT) for the
prevention of graft-versus-host disease (GvHD). Renal and
hepatic toxicities have been associated with increased
blood concentrations post alloHCT. Due to the narrow
therapeutic index of tacrolimus and variability in blood
concentrations, drug monitoring is essential. Difﬁculties
of therapeutic monitoring include dosage forms limitedFigure A. Depletion of DNMT1 in HCT116-WT and DKO cells cultured with 0.5mM de
ﬂow cytometry in a patient with relapsed AML post-transplant who was treated with p
at T+32 after reduced-intensity allo-HCT and before starting parenteral azacitidine (40
after start of azacitidine. The DNMT1 level was determined in CD34+CD117+ and S-pto capsules, drug interactions, and changes in organ
function.
Methods: All patients were initiated on 0.005 mg/kg (ideal
body weight) intravenously every 12 hours on Day -1
through a central venous catheter. Tacrolimus trough levels
were drawn twice weekly by peripheral vein (Tuesday and
Fridays). Once levels were stable in the therapeutic range (5
to 15 ng/mlddesired target between 5 to 10 ng/ml), doses
were converted to the solution formulation of 1 mg/ml
(Elefante et al BBMT 2006). Datawere collected from January
2013 to March 2014.
Results: Eighty-seven patients were admitted for alloHCT
during this time period. Of these 87 patients, 527 tacrolimus
adjustments were performed. These adjustments resulted in
12 out of greater than 10,000 levels drawn to be outside the
upper recommended range of 15 ng/ml.
Conclusions: Tacrolimus adjustments utilizing the intrave-
nous and solution dosage forms allowed doses to be adjusted
in smaller increments minimizing the frequency of toxic
trough levels.461
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